Table 3. Multivariable analysis with OS and EFS in the primary cohort of 157 CN-AML patients.
| Variable | OS, n = 157 | EFS, n = 157 | ||
|---|---|---|---|---|
| HR(95% CI) | P | HR(95% CI) | P | |
| ITPR2 expression, high VS low | 2.44 (1.39–4.28) | 0.0019 | 1.96 (1.16–3.31) | 0.012 |
| Age, per 10-y increase | 1.11 (0.97–1.28) | 0.14 | 1.05 (0.92–1.20) | 0.49 |
| Sex male VS female | 0.80 (0.52–1.25) | 0.33 | 0.96 (0.63–1.45) | 0.83 |
| NPM1, mutated VS wild type | 0.50 (0.29–0.86) | 0.012 | 0.48 (0.29–0.80) | 0.0047 |
| CEBPA, mutated VS wild type | 0.31 (0.14–0.70) | 0.0048 | 0.45 (0.21–0.96) | 0.039 |
| FLT3-ITD, mutated VS others | 1.54 (0.92–2.57) | 0.099 | 1.51 (0.92–2.48) | 0.11 |
| IDH1, mutated VS wild type | 0.81 (0.40–1.64) | 0.55 | 1.14 (0.60–2.14) | 0.69 |
| IDH2, mutated VS wild type | 0.64 (0.28–1.46) | 0.29 | 0.75 (0.32–1.74) | 0.50 |
| EVI1, mutated VS wild type | 3.03 (0.38–24.44) | 0.30 | 2.23 (0.28–17.70) | 0.45 |
| ERG expression, high VS low | 1.21 (0.73–2.03) | 0.46 | 1.21 (0.74–1.99) | 0.44 |
| BAALC expression, high VS low | 1.14 (0.67–1.92) | 0.63 | 0.99 (0.60–1.62) | 0.96 |
| LEF1 expression, high VS low | 0.53 (0.33–0.85) | 0.0086 | 0.56 (0.36–0.87) | 0.0098 |
| WT1 expression, high VS low | 0.67 (0.39–1.17) | 0.16 | 0.80 (0.48–1.35) | 0.41 |
HR, hazards ratio; CI, confidence interval.